British pharma giant GSK reports a Q3 loss due to Zantac cancer lawsuits—but CEO Emma Walmsley remains optimistic on delivering 2024 guidance

Quick Summary:

GSK suffered a loss after tax of £58 million ($75 million) in the July-September period compared with net profit of £1.5 billion one year earlier.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: AFP

Category: EconomyBusiness

Markets: United States

Topics: Cancer LondonWires Pharmaceutical Industry GSK Drugs U.K. Profits

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-30 @ 09:55:51 (2 days ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 26 words

Reading Time: 1 minutes read

Sentences: 13 lines

Sentence Length: 2 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 23337213

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 17 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 8 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions